WallStSmart

Lifestance Health Group Inc (LFST)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 4927% more annual revenue ($79.67B vs $1.58B). LLY leads profitability with a 33.5% profit margin vs 3.2%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 76/100 (B+).

LFST

Hold

48

out of 100

Grade: D+

Growth: 8.7Profit: 4.5Value: 5.7Quality: 7.0
Piotroski: 6/9Altman Z: 1.59

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LFSTUndervalued (+36.0%)

Margin of Safety

+36.0%

Fair Value

$10.83

Current Price

$12.97

$2.14 discount

UndervaluedFair: $10.83Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LFST3 strengths · Avg: 9.0/10
EPS GrowthGrowth
1927.0%10/10

Earnings expanding 1927.0% YoY

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
26.1%8/10

Revenue surging 26.1% year-over-year

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$994.92B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
33.5%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
54.2%10/10

Strong operational efficiency at 54.2%

Revenue GrowthGrowth
47.7%10/10

Revenue surging 47.7% year-over-year

EPS GrowthGrowth
26.2%8/10

Earnings expanding 26.2% YoY

Areas to Watch

LFST4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

Return on EquityProfitability
1.6%3/10

ROE of 1.6% — below average capital efficiency

Profit MarginProfitability
3.2%3/10

3.2% margin — thin

P/E RatioValuation
97.1x2/10

Premium valuation, high expectations priced in

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.623/10

Elevated debt levels

Price/BookValuation
29.4x2/10

Trading at 29.4x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : LFST

The strongest argument for LFST centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 26.1% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.

Bear Case : LFST

The primary concerns for LFST are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 97.1x leaves little room for execution misses. Thin 3.2% margins leave little buffer for downturns.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.

Key Dynamics to Monitor

LFST carries more volatility with a beta of 1.22 — expect wider price swings.

LLY is growing revenue faster at 47.7% — sustainability is the question.

LLY generates stronger free cash flow (7.8B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (76/100 vs 48/100), backed by strong 33.5% margins and 47.7% revenue growth. LFST offers better value entry with a 36.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lifestance Health Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

LifeStance Health Group, Inc., provides outpatient mental health services to children, adolescents, adults and geriatrics. The company is headquartered in Scottsdale, Arizona.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?